Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus

Area of Science:

• Rheumatology and Endocrinology
• Epidemiology of Autoimmune Diseases

Background:

• Menopause hormone therapy is widely used, but its long-term health effects require ongoing investigation.
• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with complex etiology.
• Understanding potential environmental or therapeutic triggers for SLE is crucial for prevention and management.

Purpose of the Study:

• To investigate the association between postmenopausal hormone therapy and the incidence of systemic lupus erythematosus (SLE).
• To quantify the risk of SLE development in relation to different patterns of hormone therapy use.

Main Methods:

• A prospective cohort study design was employed, utilizing data from the Nurses' Health Study.
• Followed 69,435 postmenopausal women without prior connective tissue disease from 1976 to 1990.
• Assessed hormone therapy use (never, current, past) and SLE incidence based on American College of Rheumatology criteria.

Main Results:

• Women using postmenopausal hormones had a significantly increased risk of developing SLE compared to non-users.
• Ever-users showed a 2.1-fold increased risk (95% CI, 1.1-4.0), current users 2.5-fold (95% CI, 1.2-5.0), and past users 1.8-fold (95% CI, 0.8-4.1).
• A significant trend (P=0.011) indicated that longer duration of hormone therapy use was associated with a proportional increase in SLE risk.

Conclusions:

• Postmenopausal hormone therapy use is associated with an elevated risk of developing systemic lupus erythematosus.
• Findings suggest a potential role for hormone therapy in the pathogenesis or manifestation of SLE.
• Further research is warranted to elucidate the mechanisms underlying this association.